19 Kasım 2026, Perşembe · 00:00 Piyasalar Kapalı
borsapanel.com Borsanın nabzı, tek panelde.
Abone Ol

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. The Food and Drug Administration is now requiring Biohaven to assess the potential for human toxicity from a metabolite in the drug, opakalim. Opakalim is in testing as a treatment for focal onset seizures. But, in rats, it…

Kaynak: Yahoo Finance
İlgili Haberler
Global Ares Management at td cowen conference: diversification drives growth Investing.com · 6 dk önce Global Perrigo Company stock hits 52-week high at $17.03 Investing.com · 7 dk önce Global Accelerant Holdings stock hits 52-week high at 19.91 USD Investing.com · 7 dk önce Global Zymeworks evp Scott Platshon sells $381,535 common stock Investing.com · 9 dk önce Global Alico at 18th annual Southwest IDEAS conference: land pivot gains pace Investing.com · 11 dk önce

Yorumlar (0)

Giriş yaparak yorum yazabilirsin.

İlk yorumu sen yaz.